Allarity Therapeutics (ALLR) Accounts Payables (2020 - 2026)
Allarity Therapeutics' (ALLR) quarterly Accounts Payables came in at $4.2 million in Q1 2026, down 2.58% YoY from $4.3 million in Q1 2025, and down 1.1% on a QoQ basis from $4.3 million in Q4 2025.
Allarity Therapeutics (ALLR) Accounts Payables (2020 - 2026) Analysis & Trends
Allarity Therapeutics (ALLR) has 7 years of Accounts Payables data on file, last reported at $4.2 million in Q1 2026.
- Quarterly Accounts Payables fell 2.58% year-over-year to $4.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.2 million (down 2.58% YoY) and the FY2025 annual result came in at $4.3 million, up 2.39% from the prior year.
- Accounts Payables retreated to $4.2 million in Q1 2026, from $4.3 million in the prior quarter.
- In the past five years, Accounts Payables ranged from a high of $11.1 million in Q1 2024 to a low of $4.2 million in Q4 2024.
- A 5-year average of $6.0 million and a median of $5.6 million in 2022 frame the typical range for Accounts Payables.
- Annual changes were most pronounced in 2022 — Accounts Payables soared 795.56% — and 2025, when it sank 60.69%.
- Tracing ALLR's Accounts Payables over 5 years: stood at $6.3 million in 2022, then soared by 34.63% to $8.4 million in 2023, then sank by 50.31% to $4.2 million in 2024, then increased by 2.39% to $4.3 million in 2025, then declined by 1.1% to $4.2 million in 2026.
- The last three Accounts Payables figures came in at $4.2 million (Q1 2026), $4.3 million (Q4 2025), and $4.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 35.57 Mn |
| 10 | Allarity Therapeutics | 22.75 Mn | 22.75 Mn | - | 4.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.24 Mn |
| Dec 31, 2025 | 4.28 Mn |
| Sep 30, 2025 | 4.60 Mn |
| Jun 30, 2025 | 4.61 Mn |
| Mar 31, 2025 | 4.35 Mn |
| Dec 31, 2024 | 4.18 Mn |
| Sep 30, 2024 | 4.69 Mn |
| Jun 30, 2024 | 7.75 Mn |
| Mar 31, 2024 | 11.06 Mn |
| Dec 31, 2023 | 8.42 Mn |
| Sep 30, 2023 | 6.35 Mn |
| Jun 30, 2023 | 8.09 Mn |
| Mar 31, 2023 | 6.45 Mn |
| Dec 31, 2022 | 6.25 Mn |
| Sep 30, 2022 | 5.00 Mn |
| Jun 30, 2022 | 5.56 Mn |
| Mar 31, 2022 | 5.80 Mn |
| Dec 31, 2021 | 698,000.00 |
| Sep 30, 2021 | 739,000.00 |
| Dec 31, 2020 | 2.12 Mn |